Rosiglitazone–containing Medicines (Avandia, Avandamet and Avaglim) – Important Safety Information issued by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 23/09/2010


Problem Or Issue:
Following confirmation today (23 September 2010) by the European Medicines Agency (EMA) that it is recommending the suspension of rosiglitazone-containing anti-diabetes medicines (Avandia, Avandamet and Avaglim), the Irish Medicines Board (IMB) has issued the below communication to healthcare professionals.

Rosiglitazone Healthcare Professional Communication (23 September 2010). 

The EMA recommendation has now been forwarded to the European Commission for the adoption of a legally binding decision. Further information, including a Questions and Answers document, is available from the EMA Website

The IMB previously issued a Direct Healthcare Professional Communication in relation to Rosiglitazone on 28 July 2010.

« Back